Welcome to our dedicated page for Alpha Teknova news (Ticker: TKNO), a resource for investors and traders seeking the latest updates and insights on Alpha Teknova stock.
Alpha Teknova (TKNO) drives innovation in biopharmaceutical research through critical reagents and custom media solutions. This news hub provides investors and industry professionals with essential updates on the company's scientific advancements and market position.
Access real-time press releases covering product launches, financial results, and strategic partnerships. Our curated collection includes regulatory filings, manufacturing updates, and analysis of TKNO's role in therapeutic development pipelines.
Key updates feature developments in custom growth media platforms, expansion of clinical-grade reagent production, and innovations supporting cell/gene therapy research. Track milestones in TKNO's support for vaccine development and molecular diagnostics advancements.
Bookmark this page for streamlined access to verified corporate communications. Check regularly for updates impacting TKNO's position in the $XX billion life sciences reagents market and its collaborations with leading biopharma innovators.
Teknova (Nasdaq: TKNO), a leading producer of critical reagents for therapy, vaccine, and molecular diagnostics development, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close. The company will host a webcast and conference call at 5 p.m. Eastern Time on the same day. Interested participants can access the webcast through Teknova's Investor Relations section and must register to receive a unique PIN for dial-in access. A replay will be available on the company's website approximately two hours after the event.
Teknova (Nasdaq: TKNO) and Pluristyx have launched the PluriFreeze™ cryopreservation system, now exclusively available through Teknova in the US and Canada. The innovative product line includes two key components: PluriFreeze Base, a cellular wash mimicking intracellular space, and PluriFreeze PF10, a low viscosity freezing medium with 10% DMSO.
The system is entirely synthetic and animal-origin-free, designed to streamline the development and commercialization of allogeneic cell therapies. Research-grade products are priced at $240 per 100 mL for PluriFreeze Base and $260 per 100 mL for PluriFreeze PF10, with GMP-grade versions available upon request. Free product samples are offered through March 21, 2025.
Teknova (Nasdaq: TKNO) and Pluristyx have announced a strategic collaboration where Teknova will become the exclusive manufacturer and distributor of Pluristyx's PluriFreeze™ product line in the United States and Canada. The PluriFreeze system is a novel cryopreservative and cell wash media system designed for next-generation allogeneic cell therapies.
The system consists of two key components: PluriFreeze Base, a protective wash mimicking intracellular space, and PluriFreeze PF10, a low viscosity freezing medium with 10% DMSO. The entirely synthetic and animal-origin-free system aims to streamline the scale-up process for companies developing allogeneic cell therapies.
Further details about the collaboration, including pricing and availability, will be announced at the BioProcess International West conference in San Diego, starting March 19, 2025.
Teknova (TKNO) reported its Q4 and full-year 2024 financial results, with total revenue reaching $37.7 million for FY2024, up 3% year-over-year. Q4 2024 revenue was $9.3 million, an 18% increase from Q4 2023.
Key highlights include:
- Clinical Solutions revenue grew 110% in Q4 2024 to $1.9 million
- 41% annual growth in Clinical Solutions customers
- Lab Essentials revenue reached $6.8 million in Q4, up 2%
- Year-end cash position of $30.4 million with $12.1 million in gross debt
The company improved its operational efficiency and reduced cash burn, with free cash outflow decreasing to $13.5 million in 2024 from $26.7 million in 2023. For 2025, Teknova provided revenue guidance of $39-42 million with expected free cash outflow below $12 million.
Teknova (Nasdaq: TKNO), a producer of critical reagents for therapy, vaccine, and molecular diagnostics development, has scheduled its fourth quarter and full year 2024 financial results announcement for March 4, 2025, after market close. The company will host a webcast and conference call at 5 p.m. Eastern Time on the same day. Investors can access the webcast through Teknova's Investor Relations website section, and participants requiring dial-in information need to register to receive a unique PIN number.
Teknova (TKNO) reported Q3 2024 revenue of $9.6 million, up 17% year-over-year. The company reaffirmed its 2024 revenue guidance of $35-38 million while lowering its free cash outflow outlook from $18 million to $16 million. Q3 Lab Essentials revenue remained stable at $7.2 million, while Clinical Solutions revenue grew 229% to $2.0 million. The company recorded a $2.8 million non-recurring charge related to inventory write-downs, resulting in a gross margin of 0.9%. Excluding this charge, gross margin would have been 29.8%. Total cash and short-term investments stood at $31.7 million with gross debt of $12.1 million.
Alpha Teknova (Nasdaq: TKNO), a producer of critical reagents for therapy, vaccine, and molecular diagnostics development, has announced it will release its third quarter 2024 financial results on November 7, 2024, after market close. The company will host a webcast and conference call at 5:30 p.m. Eastern Time on the same day. Investors can access the webcast through Teknova's Investor Relations website section, and participants need to register to receive dial-in information.
Teknova (NASDAQ: TKNO) reported Q2 2024 financial results, with total revenue of $9.6 million, up 3% sequentially but down 17% year-over-year. The company reaffirmed its 2024 revenue guidance of $35-38 million. Key highlights include:
- Raised $15.4 million in equity capital in July 2024
- Launched two new offerings: Express-TekSM Production and RUO+ manufacturing grade
- Clinical customers increased by 26% to 43 in the past six months
- Q2 2024 gross profit was $2.8 million with a 29.2% gross margin
- Net loss for Q2 2024 was $5.4 million, or -$0.13 per diluted share
- Free Cash Flow was -$3.0 million for Q2 2024
The company remains cautiously optimistic about market recovery and maintains its full-year outlook.
Teknova (NASDAQ: TKNO) has launched two new offerings to enhance product customization and expedite novel therapy development:
- Express-Tek℠ Production: A proprietary service that reduces custom product turnaround time by an average of two weeks, allowing products to enter production in days instead of weeks.
- RUO+ Manufacturing Grade: A new grade bridging the gap between research and clinical-grade production, providing a seamless and cost-effective option for scaling from discovery to clinical manufacturing.
These offerings aim to accelerate therapeutic development by providing faster manufacturing, delivery of critical reagents, and flexible scaling options for customers transitioning from research to clinical trials.
Alpha Teknova (Nasdaq: TKNO), a leading producer of critical reagents for novel therapies, vaccines, and molecular diagnostics, has announced its plans to report second quarter 2024 financial results on August 13, 2024, after market close. The company will host a webcast and conference call on the same day at 5:00 p.m. Eastern Time to discuss the results.
Investors and interested parties can access the live webcast through the Investor Relations section of Teknova's website or via a provided link. To participate in the call, registration is required to receive a unique PIN and dial-in information. A replay of the webcast will be available on the company's website approximately two hours after the event concludes.
